[
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
[og_img]
https://www.investing.com/news/press-releases/kura-oncology-and-kyowa-kirin-announce-fda-acceptance-and-priority-review-of-new-drug-application-for-ziftomenib-in-adults-with-relapsed-or-refractory-npm1mutant-aml-93CH-4074491
Investing.com
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
Related articles
